Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Ionis Pharmaceuticals Inc (IONS)

489 + Investors. Track Smart Money conviction in IONS. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +1
Streak
4Q ▲
Buyers last Q
53%

Smart Money Signals — IONS

Based on 494 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 4 quarters in a row

last 6Q
For 4 consecutive quarters, more hedge funds added IONS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
494 hedge funds hold IONS right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +44% more funds vs a year ago

fund count last 6Q
+152 new funds entered over the past year (+44% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 53% buying

262 buying235 selling
Last quarter: 262 funds bought or added vs 235 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-39 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 80 → 116 → 113 → 74. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

56% of holders stayed for 2+ years

■ 56% conviction (2yr+) ■ 22% medium ■ 22% new
276 out of 494 hedge funds have held IONS for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
➡️

Steady discovery — ~74 new funds/quarter

55 → 80 → 116 → 113 → 74 new funds/Q
New funds entering each quarter: 80 → 116 → 113 → 74. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 64% veterans vs 26% newcomers

■ 64% veterans ■ 10% 1-2yr ■ 26% new
Entry-cohort mix of 521 holders: 336 (64%) are 2+ year veterans, 52 entered 1–2 years ago, and 133 (26%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 54% AUM from top-100 funds

54% from top-100 AUM funds
62 of 491 holders are among the 100 largest funds by AUM, controlling 54% of total institutional value in IONS. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
4.1
out of 10
Moderate Exit Risk
Exit risk score 4.1/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — IONS

In 2026 Q1, 262 hedge funds were net buyers of IONS (74 opened a new position, 188 added to an existing one), while 235 reduced or exited (162 trimmed, 73 sold completely) — a 53% buyer ratio, indicating a slight buying edge. This marks 4 consecutive quarters of net institutional buying — a persistent conviction signal. 54% of total institutional value in IONS is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +1 funds (more new holders than closures). Total institutional holders: 494.

Hedge Fund Ownership: IONS

How many hedge funds hold IONS — quarterly history vs. share price
Quarterly hedge fund ownership of IONS vs. share price

Market Analysis: IONS

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: IONS

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Ionis Pharmaceuticals Inc (IONS) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much IONS has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 87d ago
IONS
+5.0%
XLV
+9.3%

IONS outperformed XLV by -4.3% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 42d ago
IONS
+6.3%
XLV
+10.5%

Since the filing became public, IONS outperformed XLV by -4.2% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

32 top-rated funds 10 high-conviction
Consensus
6.6
/ 10
breadth
×
Elite
4.3
/ 10
conviction
Hedge Fund Positioning: IONS
489 + Investors

Track Smart Money conviction in IONS. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 489 493 -0.81%
13F Shares 176M 170M 3.29%
Total Value $12.36B $13.19B -6.3%
New Positions 71 113 -42
Increased Positions 183 166 +17
Closed Positions 75 57 +18
Reduced Positions 151 143 +8
Total Calls 17 21 -19.05%
Total Puts 13 16 -18.75%
PUT/CALL Ratio 0.76 0.76 Neutral

Statistics: IONS

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

489 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in IONS. Verified SEC 13F-HR filings.

QUARTER:
Top 25 IONS holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Tweedy, Browne Co LLC 13.57% 2,275,625 $170.9M
2 Boone Capital Management LLC 11.51% 500,522 $37.6M
3 Davern Capital Partners, LP 7.97% 386,903 $29.1M
4 Orion Investment Co 5.36% 225,015 $16.9M
5 Privium Fund Management B.V. 4.53% 290,024 $21.8M
6 Exome Asset Management LLC 4.27% 110,064 $8.3M
7 Bellevue Group AG 3.25% 1,818,665 $136.6M
8 Sicart Associates LLC 3.07% 159,412 $12.0M
9 Sector Gamma As 3.00% 169,468 $12.7M
10 Summit Partners Public Asset Management, LLC 2.83% 1,404,033 $105.4M
11 Arrowpoint Investment Partners (Singapore) Pte. Ltd. 2.60% 38,988 $2.9M
12 Eversept Partners, LP 2.50% 632,100 $47.5M
13 Deep Track Capital, LP 2.39% 1,950,000 $146.4M
14 Artia Global Partners LP 2.17% 144,376 $10.8M
15 Deerfield Management Company, L.P. 1.75% 1,979,669 $148.7M
16 Future Fund LLC 1.55% 58,732 $4.4M
17 AlphaCentric Advisors LLC 1.47% 19,587 $1.5M
18 Lisanti Capital Growth, LLC 1.43% 75,699 $5.7M
19 DCF Advisers, LLC 1.12% 56,000 $4.2M
20 Ground Swell Capital, LLC 1.08% 7,285 $547K
21 Summit Partners Public Asset Management, LLC 0.91% 450,000 $33.8M
22 Groupama Asset Managment 0.90% 824,540 $61.9M
23 Baker BROS. Advisors LP 0.88% 2,047,727 $153.8M
24 Rhenman & Partners Asset Management AB 0.86% 92,900 $7.0M
25 Capstone Capital Management Ltd 0.84% 21,447 $832K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Ionis Pharmaceuticals Inc (IONS)

What does the Smart Money Trend signal show for IONS?

Buying streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds added IONS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for IONS?

Slight buying edge — 53% buying: Last quarter: 262 funds bought or added vs 235 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for IONS holders?

Elite ownership — 54% AUM from top-100 funds: 62 of 491 holders are among the 100 largest funds by AUM, controlling 54% of total institutional value in IONS. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held IONS?

56% of holders stayed for 2+ years: 276 out of 494 hedge funds have held IONS for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Ionis Pharmaceuticals Inc (IONS) following the 2026 Q1 hedge fund 13F filings?

As of today, IONS has moved +6.3% since the 2026 Q1 13F filing date (May 15, 2026), compared to +10.5% for the XLV sector ETF — an outperformance of -4.2%. Since the quarter end (March 31, 2026), IONS has gained +5.0% vs +9.3% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →